Methods Inf Med 2015; 54(01): 24-31
DOI: 10.3414/ME13-02-0025
Focus Theme – Original Articles
Schattauer GmbH

Bridging Data Models and Terminologies to Support Adverse Drug Event Reporting Using EHR Data[*]

G. Declerck
1   INSERM UMRS 1142, Paris, France
,
S. Hussain
1   INSERM UMRS 1142, Paris, France
,
C. Daniel
1   INSERM UMRS 1142, Paris, France
,
M. Yuksel
2   SRDC Ltd, Ankara, Turkey
,
G. B. Laleci
2   SRDC Ltd, Ankara, Turkey
,
M. Twagirumukiza
3   AGFA HealthCare, Mortsel, Belgium
,
M. -C. Jaulent
1   INSERM UMRS 1142, Paris, France
› Author Affiliations
Further Information

Publication History

received: 15 June 2013

accepted: 17 March 2014

Publication Date:
22 January 2018 (online)

Preview

Summary

Introduction: This article is part of the Focus Theme of Methods of Information in Medicine on “Managing Interoperability and Complexity in Health Systems”.

Background: SALUS project aims at building an interoperability platform and a dedicated toolkit to enable secondary use of electronic health records (EHR) data for post marketing drug surveillance. An important component of this toolkit is a drug-related adverse events (AE) reporting system designed to facilitate and accelerate the reporting process using automatic prepopulation mechanisms. Objective: To demonstrate SALUS approach for establishing syntactic and semantic inter-operability for AE reporting.

Method: Standard (e.g. HL7 CDA-CCD) and proprietary EHR data models are mapped to the E2B(R2) data model via SALUS Common Information Model. Terminology mapping and terminology reasoning services are designed to ensure the automatic conversion of source EHR terminologies (e.g. ICD-9-CM, ICD-10, LOINC or SNOMED-CT) to the target terminology MedDRA which is expected in AE reporting forms. A validated set of terminology mappings is used to ensure the reliability of the reasoning mechanisms.

Results: The percentage of data elements of a standard E2B report that can be completed automatically has been estimated for two pilot sites. In the best scenario (i.e. the avail able fields in the EHR have actually been filled), only 36% (pilot site 1) and 38% (pilot site 2) of E2B data elements remain to be filled manually. In addition, most of these data elements shall not be filled in each report.

Conclusion: SALUS platform’s interopera bility solutions enable partial automation of the AE reporting process, which could con tribute to improve current spontaneous reporting practices and reduce under-report ing, which is currently one major obstacle in the process of acquisition of pharmacovigilance data.

* Supplementary material published on our web-site www.methods-online.com